~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

Gilead’s Trodelvy approved for triple-negative breast cancer in US

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC